Jennifer Byrne

2 weeks ago | healio.com | Jennifer Byrne

Key takeaways: Believe in You helps cancer survivors prepare for the annual Dolphins Cancer Challenge, which includes a 5K and bike rides. The program offers training to patients and survivors and encourages year-round fitness. The Miami Dolphins’ annual Dolphins Cancer Challenge has been the biggest fundraising event in the NFL for the past 15 years, contributing $90 million toward research at Sylvester Comprehensive Cancer Center at University of Miami.

2 weeks ago | healio.com | Jennifer Byrne |Heather Biele

Key takeaways: The need for long-term survivorship care is well known but has not been effectively integrated, researchers say. A care model proposed by researchers requires a team-based approach and technological solutions. A proposed cancer survivorship model that involves interdisciplinary coordination and the use of digital tools has the potential to “move the outcomes needle,” according to researchers. In a paper published in JCO Oncology Practice, Steven J.

2 weeks ago | healio.com | Jennifer Byrne

Key takeaways: The Oncology Core Education and Networking program provides over 20 hours of live virtual learning. Nearly 82% of nurse participants are still employed at 1 year — 12% higher than the national average. An initiative developed by The US Oncology Network has demonstrated effectiveness for addressing the ongoing shortage of oncology nurses, as well as high turnover rates in the profession.

2 weeks ago | healio.com | Jennifer Byrne |Heather Biele

Key takeaways:Patients with normal labs and no treatment-related symptoms could bypass an in-patient visit and proceed to immunotherapy. Patients who used the text-based system saved more than 60 minutes per visit. A text message-based electronic triage system showed efficacy for collecting patient-reported treatment outcomes and minimizing the time burden of cancer care, according to results of a pilot study.

2 weeks ago | healio.com | Jennifer Byrne

Key takeaways: Inpatient immune checkpoint inhibitor use yielded median survival of only 1.5 months. Researchers emphasized the importance of understanding the effects of oncology drugs on hospitalized patients. Use of immune checkpoint inhibitors in an inpatient setting appeared associated with poor outcomes, according to research published in JCO Oncology Practice. More than half of hospitalized patients who received these agents survived less than 2 months.